dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Camidge, D. Ross |
dc.contributor.author | Ahn, Myung-Ju |
dc.contributor.author | Yang, James C. H. |
dc.contributor.author | Han, Ji-Youn |
dc.contributor.author | Hochmair, Maximilian J. |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Kim, Hye Ryun |
dc.date.accessioned | 2021-09-23T11:08:10Z |
dc.date.available | 2021-09-23T11:08:10Z |
dc.date.issued | 2020-11-01 |
dc.identifier.citation | Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592–603. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/6346 |
dc.description | Càncer de pulmó; Brigatinib; Estudi ALTA-1L |
dc.description.sponsorship | Supported by ARIAD Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Professional medical writing assistance was provided by Lauren Gallagher, RPh, PhD, and Lela Creutz, PhD, of Peloton Advantage, Parsippany, NJ, an OPEN Health company, and funded by Millennium Pharmaceuticals. Supported by National Health Service funding to the Royal Marsden Hospital/Institute of Cancer Research NIHR Biomedical Research Centre (S.P.). |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;38(31) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic - Eficàcia |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Progression-Free Survival |
dc.title | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.20.00505 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://doi.org/10.1200/JCO.20.00505 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Camidge DR] University of Colorado Cancer Center, Aurora, CO. [Kim HR] Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. [Ahn MJ] Samsung Medical Center, Seoul, South Korea. [Yang JCH] National Taiwan University Hospital, Taipei, Taiwan. [Han JY] National Cancer Center, Goyang, South Korea. [Hochmair MJ] Department of Respiratory and Critical Care Medicine, Krankenhaus Nord–Klinik Floridsdorf, Vienna, Austria. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 32780660 |
dc.identifier.wos | 000588411100004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |